To identify pharmacokinetic drug-drug interactions between tipranavir/ritonavir (TPV/r) and, rosuvastatin and atorvastatin, we conducted two prospective, open-label, single arm, patients. This association is possibly explained by dyslipidemia. Since the HIV patient 14 population is getting older, it is critical to control hyperlipidemia in PI-treated patients in 15 order to reduce the risk of long-term cardiovascular complications. Potent 3-hydroxy-3-16 methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (e.g., atorvastatin and 17 rosuvastatin) are recommended for the treatment of hypercholesterolemia (2) 
-2 -two-period studies. The geometric mean ratio (GMR) was 1.37 (90% confidence interval, concentrations. 28 However, rosuvastatin is unlikely to interact with TPV/r since it is not a CYP3A4 29 substrate and it is not extensively metabolized (1) . In order to provide guidance for 30 clinical use, pharmacokinetic studies in healthy volunteers evaluated the drug-drug 31 interactions between steady-state TPV/r and single-dose rosuvastatin (Rosuvastatin 32 Study) and atorvastatin (Atorvastatin Study). 33
34

MATERIALS AND METHODS
35
Subjects. 36
Each study protocol was approved by the local institutional review board, and 37 written informed consent was obtained from all volunteers before enrollment in these 38 studies. were eligible for this study. Subjects were considered to be healthy based on their 52 medical histories, physical examination, electrocardiogram, urinalysis, routine tests of 53 biochemistry and hematology, and hepatitis B, C, and HIV status. Throughout the study 54 period, subjects were instructed to abstain from alcohol, grapefruit/grapefruit juice 55 (starting 10 d prior to the first study day), Seville oranges, and over-the-counter herbal 56 
Atorvastatin Study 83
The single-dose pharmacokinetics of atorvastatin, ortho-hydroxy-atorvastatin, and para-84 hydroxy-atorvastatin were assessed on day 1 after ingestion of 40 mg atorvastatin 85 (Lipitor; Pfizer Inc; New York, NY) alone. From day 14 to 21 subjects received TPV/r 86 500 mg/200 mg twice daily TPV/r dosages from Day 13 evening to Day 18 morning were 87 taken at home. All dosages before and after this period were DOT. Subjects were asked to 88 log their adherence to study medications. All subjects had 100% adherence with study 89 On pharmacokinetic sampling days, atorvastatin and TPV/r were administered 102 orally at 8 AM with 240 ml of water after an overnight fast. A light snack (i.e., 240 ml of 103 low-fat milk/dry bread) was allowed at no less than 1 h prior to dosing or 2 h after dosing 104 to minimize nausea and vomiting if necessary. Subjects were kept in an upright position 105 for the first 2 h after drug administration. A standardized lunch and dinner were served 4 106 and 10 h after the morning dose, respectively (500 to 682 Kcal, 23% to 25% from fat). 107
Total daily fluid intake was restricted to a maximum of 3 L. 108 High and low calibration ranges were used to predict unknown concentrations. 150
The high calibration curve ranged from 20,000 ng/ml to 1,000 ng/ml. The low calibration 151 curve ranged from 2,000 ng/ml to 25.0 ng/ml. 152
153
Data analysis and statistical methods. 154
Pharmacokinetic analysis 155
For both studies, noncompartmental methods were used for pharmacokinetic analysis 156 Lack of a clinically relevant interaction was declared if the 90% confidence interval of 175 the GM ratio was completely contained in the acceptance range of 0.80 to 1.25. 176 Prior to statistical analysis of the effect of TPV/r on atorvastatin (day 1 versus day 177 20), the atorvastatin AUC 0-∞ and C max were multiplied by four to adjust for the difference 178 in atorvastatin dose between day 1 (40 mg) and day 20 (10 mg). No dose adjustments 179
were made for the analysis of the hydroxy-metabolite concentrations. 180
In addition to the analysis of atorvastatin and its hydroxy-metabolites 181 individually, the effect on total HMG-CoA reductase inhibitory activity was assessed. 182
The total HMG-CoA reductase inhibitory activity was calculated as the sum of the time- curve (AUC) was 38.6 ng·hr/ml, a 37% increase compared with rosuvastatin alone (P = 207 0.0006) (Figure 1, Figure 2 ). The rosuvastatin GM maximum plasma concentration 208 (C max ) was 5.78 ng/ml with TPV/r coadministration, a 123% increase compared with 209 rosuvastatin alone (P < 0.001) ( Table 1 ). Rosuvastatin clearance also was decreased by 210 27% with TPV/r coadministration; this resulted in a significant increase in plasma half-211 life (t 1/2 ; 20.6 h versus 9.01 h; P < 0.001). Tipranavir and ritonavir pharmacokinetic 212 parameters were not affected by single-dose rosuvastatin (Table 3) . 213
214
Safety 215
The most common AEs associated with study drug administration were diarrhea (10.3%), 216 nausea (13.8%), abdominal cramp (10.3%), flatulence (10.3%), headache (13.8%), and 217 grade 1 liver enzyme elevations (34.5%) not resulting in study drug discontinuation. With 218 the exception of one grade 2 nausea, one grade 2 rash, and eight grade 2 to 3 liver 219 enzyme elevations, all AEs were of mild intensity (grade 1). Of 29 subjects enrolled, 13 220 subjects did not complete the study. Eight subjects discontinued because of grade 2 to 3 221 liver enzyme elevations, which were reversible upon study drug discontinuation. None of 222 the subjects who had an increase in liver enzyme levels developed signs or symptoms of 223 clinical hepatitis. One subject withdrew because of a grade 3 hypersensitivity reaction 224 (mild shortness of breath, diffuse rash, and liver enzyme elevations). Three subjects 225 withdrew consent, and one subject was administratively discharged due to a positive drug 226 Single-dose atorvastatin did not affect the steady-state pharmacokinetics of 257 tipranavir (Table 3) . 258
259
Safety 260
In general, treatment with TPV/r 500 mg/200 mg twice daily alone and in the presence of 261 single-dose atorvastatin was well tolerated in this study. There were no study 262 discontinuations due to AEs or for any other reason. One serious AE was reported in this 263 study (sprained ankle due to exercise), which was unrelated to the study drugs. another PI, lopinavir/ritonavir (LPV/r), when coadministered with rosuvastatin at steady 344 state. A prospective study conducted in healthy volunteers found that rosuvastatin AUC 0-345 ∞ and C max were increased 2.1-and 4.7-fold, respectively, when coadministered with 346 LPV/r (15) . Similar to the current atorvastatin study, the t 1/2 was not affected; however, 347 the magnitude of drug interaction observed between rosuvastatin and LPV/r was several-348 fold higher. This effect may be due to the higher inhibitory potency of BCRP observed 349 with lopinavir in vitro (28) . Coadministration of atazanavir/ritonavir with rosuvastatin 350 was found to result in a 210% increase in rosuvastatin AUC; however, no significant 351 (statins) is rhabdomyolysis, which can result in significant morbidity and mortality (22) . 377
Although rhabdomyolysis may occur in 0.1% to 0.5% of the population when statins are 378 prescribed as monotherapy, the risk is greatly increased when drugs that inhibit CYP3A4-379 mediated metabolism are used concomitantly (22) . Several cases of atorvastatin-380 associated rhabdomyolysis have been reported in patients using atorvastatin in 381 combination with CYP3A4 inhibitors such as cyclosporine or delavirdine (4, 19) . 382
Although the safety and efficacy of rosuvastatin and atorvastatin could not be assessed by 383 these single-dose studies, to minimize the risk of rhabdomyolysis, careful monitoring for 384 any signs or symptoms of toxicity is recommended. Alternatively, statins with a lower 385 likelihood of interactions could be considered. 386
In conclusion, we observed a clinically relevant increase in rosuvastatin and 387 atorvastatin concentrations during coadministration of TPV/r 500 mg/200 mg twice daily. a Dose-adjusted assuming linear pharmacokinetics for atorvastatin (normalized = observed value X 4).
b Calculated as the ratio of atorvastatin + TPV/r to atorvastatin alone.
c P value for difference between atorvastatin alone and atorvastatin + TPV/r using the Wilcoxon matched pairs signed ranks test. 
